Therapeutic Delivery – Products

Aptamer Group presented new data on its Optimer therapeutic delivery vehicle for liver fibrosis, showing its potential for broad applicability in fibrotic diseases at the ASGCT 2025 Annual Meeting.

Aptamer licenses Optimers to the University of Glasgow for use in swine vaccines, targeting global animal health markets.

Cyprumed and MSD have partnered to develop oral peptide formulations using Cyprumed’s drug delivery technology.

BOC Sciences adds to its participation agenda the prestigious Drug Discovery Chemistry 2025 Conference (April 14-17, 2025), which will be a hybrid event taking place in San Diego, CA, and will offer virtual access for worldwide attendees.

LGM Pharma announces a $6M investment to expand its Rosenberg, Texas facility, enhancing its capacity for liquid, semi-solid and suppository drug production. The expansion supports growing prescription drug demand.

Lyndra Therapeutics, a clinical-stage biopharmaceutical company, announced a strategic collaboration with Thermo Fisher Scientific Inc.

LNP developers now have access to bench-to-patient lipid synthesis support from a single partner.

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce three new members to its Scientific Advisory Board (SAB).

Thermo Fisher Scientific has introduced the Invitrogen Vivofectamine™ Delivery Solutions to provide high-performance lipid nanoparticles (LNP) technology for non-viral delivery of nucleic acids.

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders, is pleased to announce that a genetic medicines customer has selected to progress to the final commercial development phase for Optimer delivery vehicles.